MedTrace Logo

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT06563323 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-03-06

No results posted yet for this study

Summary

A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)

Conditions

  • Pyoderma Gangrenosum
  • Skin Diseases
  • Wound Heal
  • Pyoderma
  • Skin Ulcer

Interventions

DRUG

Guselkumab

Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Ohio State University

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Alex G Ortega-Loayza, MD, MCR · Oregon Health and Science University, Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2027-08-13
Completion
2027-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06563323 on ClinicalTrials.gov